viewAnteris Technologies Ltd

Admedus raises $2.76 million from share purchase plan

Admedus is a medical technologies company with numerous catalysts on the horizon.

AHZ revenue split
Revenue is derived by the ADAPT® and Infusion business divisions

Admedus Ltd (ASX:AHZ) shareholders have subscribed for 9.2 million shares priced at 30 cents raising $2.76 million in funding under a share purchase plan (SPP).

The SPP follows a placement also priced at 30 cents in early-mid May which raised about $6 million.

SPP funds will help to facilitate further expansion and acceleration of its new product pipeline, including TAVR and the unique 3D shaped tissue portfolio.

READ: Admedus secures $6 million to expand medical technologies strategy

Transcatheter aortic valve replacement (TAVR) is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.

Admedus’ new TAVR device is designed to reduce the risks associated with the insertion and placement of the valve.

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

Market: ASX
Market Cap: $23.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read